申聯生物(688098.SH):取消建設募投項目“懸浮培養口蹄疫滅活疫苗項目”第二條生產線
格隆匯 2 月 22日丨申聯生物(688098.SH)公佈,公司於2021年2月22日召開了第二屆董事會第十九次會議,審議通過了《關於變更募投項目的議案》,決定取消建設募投項目“懸浮培養口蹄疫滅活疫苗項目”第二條生產線,同時將募投項目投資總額調減19108萬元,投資總額由86810萬元調整為67702萬元,擬使用募集資金額由40017.5萬元調整為25892萬元。上述事項尚需提交公司股東大會審議。公司監事會、獨立董事和保薦機構國信證券股份有限公司對上述事項出具了明確的同意意見。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.